Amy Parison
Senior VP & CFOMs. Amy Parison was Senior Vice President of Finance at Editas Medicine, Inc. since January 2025 until March 28, 2025 and serves as its Chief Financial Officer since March 28, 2025 and is Senior Vice President since 2025. She joined Editas in August 2022. During her time at Editas, she has served in multiple roles of increasing responsibilities including Senior Vice President, Finance and Vice President and Corporate Controller. In partnership with the ELT, she worked on equity financings, licensing transactions and royalty monetization. Prior to Editas, Ms. Parison served as Corporate Controller of Rubius Therapeutics where she led the accounting team following the Company’s IPO, building critical business and financial processes. Prior to Rubius, she was at Vertex Pharmaceuticals, where she held several roles of increasing responsibility within the accounting and finance teams and supported forecasting, budgeting and business development. She started her career with PricewaterhouseCoopers, LLP. Ms. Parison holds a BS and a Master of Accounting, both from Babson College.
Positions
- Company NameEditas Medicine, Inc.Stock CodeEDITPositionSenior VP & CFOColleagues
- GOGilmore O’NeillPresident, CEO & Director
- JHJessica HopfieldIndependent Chairman
- LCLinda C. BurklyExecutive VP & Chief Scientific Officer
- FZFeng ZhangCo-Founder & Scientific Advisory Board Member
- GMGeorge McDonald ChurchCo-Founder & Scientific Advisory Board Member
- AJAndrew J. HirschIndependent Director
